Speakers bureau: Speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Pfizer and Roche

DOI: 10.1136/annrheumdis-2020-eular.5612

OP0252

CIRCULATING COLLAGEN TURNOVER MARKERS ARE SPECIFICALLY CHANGED IN VERY EARLY SYSTEMIC SCLEROSIS

R. Dobrota¹, S. Jordan¹, P. Juhl², B. Maurer¹, M. O. Becker¹, C. Mihai¹, A. C. Bay-Jensen², M. Karsdal², A. S. Siebuhr², O. Distler¹. ¹University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland; ²Nordic Bioscience, Herlev, Denmark

Background: Timely diagnosis of patients with very early systemic sclerosis (veSSc) is essential for their personalized and optimal management. We hypothesise that changes in serum-based extracellular matrix (ECM) turnover biomarkers are already detectable in patients with veSSc, even before occurrence of specific clinical signs.

Objectives: To investigate circulating ECM turnover markers as potential biomarkers for veSSc.

Methods: Patients with veSSc, n=42, defined as presence of Raynaud's syndrome and at least one of puffy fingers, positive antinuclear antibodies or pathological nailfold capillaroscopy, who did not meet any classification criteria for SSc, were compared to healthy controls (HC, n=29). Longitudinal assessment, data and sera collection were conducted by EUSTAR standards. ECM-degradation (BGM, C3M, C4M, C6M) and ECM-formation biomarkers (PRO-C3, PRO-C4, PRO-C5) were measured in serum using ELISA assays. The statistical analyses included Mann-Whitney U, Spearman correlation and ROC analysis. Using Kaplan-Meier plots and univariable Cox regression, we explored if biomarkers can predict progression towards definite SSc (fulfillment of ACR/EULAR criteria or minimum two points increase in the criteria score) during the longitudinal follow-up.

Results: Compared to HC, veSSc patients showed a deregulated turnover of type III and IV collagen, with higher degradation (higher C3M, C4M, both $p < 0.0001$ and PRO-C3, $p = 0.004$, Figure 1a, resulting in lower turnover ratios PRO-C3/C3M and PRO-C4/C4M, both $p < 0.0001$). The biglycan degradation biomarker BGM was also higher in veSSc ($p = 0.006$), whereas the degradation biomarker for type VI collagen, C6M, was lower than in HC ($p = 0.002$). In the ROC analysis, biomarkers of type III and IV collagen distinguished between veSSc and HC: C3M, AUC=0.95, $p < 0.0001$; C4M, AUC=0.97, $p < 0.0001$; turnover ratios PRO-C3/C3M, AUC=0.80, $p < 0.0001$; PRO-C4/C4M, AUC=0.97; $p < 0.0001$ (Figure 1b).

Median follow up was 4.5 years (range 0.5-7.9 years), mean age was 50 ± 2.2 years, 88% female gender, 24% with puffy fingers, 92% were ANA positive, 64% had an abnormal capillaroscopy, none had organ involvement or skin fibrosis. 14/42 veSSc patients fulfilled the ACR/EULAR classification criteria at follow-up (time to fulfilment of criteria ranged between 0.5 and 6.8 years from inclusion) and in addition, 18/42 veSSc patients gained at least two classification criteria-points. This resulted in 14, respectively 18 progressors for the longitudinal analysis. However, in univariable Cox regression, the baseline levels of the markers did not predict progression over time.

Figure 1a. Levels of biomarkers in healthy controls (HC), and very early SSc (veSSc)

Figure 1a. Legend
A) Formation biomarkers: PRO-C3-formation fragment of collagen type III; PRO-C4-aminoterminal pro-peptide of procollagen type IV; PRO-C5-formation fragment of collagen type V;
B) Degradation biomarkers: C3M-degradation fragment of collagen III by MMP-9; C4M-degradation fragment of collagen type IV by MMPs; C6M-degradation fragment of collagen VI by MMP-2/9; BGM-degradation fragment of biglycan by MMP-9/12;
C) Turnover ratio of PRO-C3/C3M and PRO-C4/C4M

Figure 1b. ROC analysis in healthy controls (HC) vs. very early SSc (veSSc)

Conclusion: ECM turnover is already altered in veSSc patients compared to HC. Biomarkers of type III and IV collagen distinguished between veSSc patients and HC, which may indicate them as potential biomarkers for the detection of veSSc in addition to the established immunological and capillaroscopic criteria.

Disclosure of Interests: Rucsandra Dobrota: None declared, Suzana Jordan: None declared, Pernille Juhl Employee of: Nordic Bioscience, Britta Maurer Grant/research support from: AbbVie, Protogen, Novartis, congress support from Pfizer, Roche, Actelion, and MSD, Speakers bureau: Novartis, Mike O. Becker: None declared, Carina Mihai: None declared, Anne-Christine Bay-Jensen Shareholder of: Nordic Bioscience A/S, Employee of: Full time employee at Nordic Bioscience A/S., Morten Karsdal Shareholder of: Nordic Bioscience A/S., Employee of: Full time employee at Nordic Bioscience A/S., Anne Sofie Siebuhr Employee of: Nordic Bioscience, Oliver Distler Grant/research support from: Grants/Research support from Actelion, Bayer, Boehringer Ingelheim, Competitive Drug Development International Ltd. and Mitsubishi Tanabe; he also holds the issued Patent on mir-29 for the treatment of systemic sclerosis (US8247389, EP2331143)., Consultant of: Consultancy fees from Actelion, Acceleron Pharma, AnaMar, Bayer, Baecon Discovery, Blade Therapeutics, Boehringer, CSL Behring, Catenion, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, GSK, Glenmark Pharmaceuticals, Inventiva, Italfarmaco, IQvia, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Roche, Sanofi and UCB, Speakers bureau: Speaker fees from Actelion, Bayer, Boehringer Ingelheim, Medscape, Pfizer and Roche

DOI: 10.1136/annrheumdis-2020-eular.5683

OP0253

AUTOANTIBODY STATUS IN DERMATOMYOSITIS AND POLYMYOSITIS PATIENTS DEFINES BOTH CANCER RISK AND SURVIVAL WITH ANA NEGATIVITY IN CASES WITH CONCOMITANT CANCER HAVING A WORSE SURVIVAL

A. Watad¹, D. McGonagle², M. Lida³, N. L. Bragazzi⁴, D. Comanesther⁵, A. Cohen⁵, H. Amital¹. ¹Sheba Medical Center, Department of Medicine B; Rheumatology Unit, Tel Aviv, Israel; ²Leeds Musculoskeletal Biomedical Research Unit, Rheumatology, Leeds, United Kingdom; ³Sheba Medical Center, Rheumatology Unit, Ramat Gan, Israel; ⁴University of Genoa, Genova, Italy; ⁵Clalit Health Services, Tel Aviv-Yafo, Israel

Background: We previously reported that ANA-negative cases with systemic sclerosis (SSc) and concomitant cancer had a worse survival than ANA-positive cases with associated cancer possibly suggesting that humoral mediated autoimmunity conferred a survival advantage (1). Dermatomyositis (DM) and polymyositis (PM) are two immune-mediated myopathies associated with numerous autoantibodies.

Objectives: The present large-scale, population-based study tested the hypothesis that humoral autoimmunity associated with cancer in solid/haematological malignancies impacted on DM/PM patient survival.

Methods: Over 2000 cases with either DM or PM were recruited from the Clalit Health Service (CHS) chronic diseases registry, one of the largest healthcare maintenance Israeli organization, serving approximately half of the entire country's population. Over 10000 matched controls were recruited. The data collected range from 2000 to 2018.

Results: Altogether 12,278 subjects were recruited (2,085 cases, and 10,193 controls, 5,042 males, 41.1%, and 7,236 females, 58.9%). Among cases, 1,475 individuals (70.7%) were diagnosed with DM, whereas 610 (29.3%) with PM. Mean age was 47.81 ± 22.51 years. 1,379 cases of cancers (11.2%) were diagnosed. At the univariate analysis and as expected, the rate of malignancies was

significantly ($p < 0.0001$) higher in DM/PM ($n = 361$, 17.3%) with respect to controls ($n = 1,018$, 10.0%).

Concerning prognosis, ANA positivity in PM/DM was associated with a better prognosis for all cancers (OR 0.39 [95% CI 0.24-0.63], $p = 0.0001$). For individual cancer types; thyroid cancer (OR 0.39 [95% CI 0.24-0.63], $p = 0.0001$), gastric cancer (OR 0.40 [95% CI 0.25-0.64], $p = 0.0001$), kidney cancer (OR 0.39 [95% CI 0.24-0.62], $p = 0.0001$), acute leukaemia (OR 0.40 [95% CI 0.25-0.65], $p = 0.0002$), non-Hodgkin's lymphoma (OR 0.39 [95% CI 0.25-0.63], $p = 0.0001$), but not for myelodysplastic syndrome.

The main cancers linked to PM/DM were thyroid cancer (OR 3.17 [95% CI 2.27-4.43]), gastric cancer (OR 5.96 [95% CI 4.24-8.38]), kidney cancer (OR 3.83 [95% CI 1.02-14.31], $p = 0.0462$), and myelodysplastic syndrome (OR 2.01 [95% CI 1.17-3.46], $p = 0.0111$). Regarding gastric cancer, positivity for anti-RNP (OR 5.68 [95% CI 3.02 to 10.71], $p < 0.0001$), anti-SSA (OR 21.99 [95% CI 11.21 to 43.14], $p < 0.0001$), and anti-Jo1 (OR 12.23 [95% CI 7.12 to 21.01], $p < 0.0001$) was associated with a higher risk of cancer development.

Conclusion: ANA positivity is an independent predictor of favorable prognosis in PM/DM patients with cancer, possibly suggesting that cancer directed humoral autoimmunity may have some benefit. Therefore, humoral autoimmunity in SSc and PM/DM is a broad mechanism that confers a survival advantage and is relevant for disease understanding and elucidating optimal anti tumoural immunity in the current age of cancer immunotherapy.

References:

- Watah A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. *Oncoimmunology*. 2019 Mar 24;8(6):e1588084.

Disclosure of Interests: Abdulla Watah: None declared, Dennis McGonagle Grant/research support from: Janssen Research & Development, LLC, Merav Lidar: None declared, Nicola Luigi Bragazzi: None declared, Doron Comaneshter: None declared, Arnon Cohen: None declared, Howard Amital: None declared

DOI: 10.1136/annrheumdis-2020-eular.5977

OP0254

CHROMATIN CONFORMATION SIGNATURE ANALYSIS IN EARLY VS LATE SCLERODERMA PHENOTYPES

M. Galloway¹, E. Hunter², A. Akoulitchev², S. Vigneswaran¹, B. Abdi¹, C. Denton¹, D. Abraham¹, R. Stratton¹. ¹UCL Division of Medicine Royal Free Campus, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom; ²Oxford Biodynamics Plc, Oxford, United Kingdom

Background: Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease in which clinical outcomes vary widely. Predicting outcomes on an individual basis remains challenging despite progress made through autoantibody analysis and gene expression profiling. Effective targeted therapies are evolving and accurately predicting outcomes is important to enable patient stratification for therapy.

Chromatin Conformation Signature (CCS) profiling of peripheral blood for systemic epigenetic deregulations could be used for such a purpose. The EpiSwitch platform offering high throughput and resolution chromosome conformation (3C) capture detects significant regulatory changes in 3D genome architecture and maps long range interaction between distant genomic locations. This then reveals the spatial disposition and physical properties of the chromosome, such as chromatin loops and inter-chromosomal connections, which have a role in network organization and genetic epistasis controlling gene expression. EpiSwitch automated platform has been successfully utilised in patient stratification in RA, MS and other indications.

This methodology could be applied to patients with SSc to identify CCS associated with different phenotypes and may ultimately be used to stratify and identify patients into pathogenic subtypes.

Objectives: We aimed to determine significant CCSs associated with early and late phenotypes of SSc.

Methods: The EpiSwitch-based chromosome conformation capture (3C) method was applied to blood samples from early phenotype, and late phenotype SSc patients. Intact nuclei were isolated from peripheral blood mononuclear cells and subjected to formaldehyde fixation resulting in crosslinking between physically touching segments of the genome via contacts between their DNA bound proteins. For quantification of cross-linking frequencies, the cross linked DNA was digested and then subjected to ligation. Cross-linking was then reversed and individual ligation products detected and quantified by EpiSwitch custom oligo array annotated across the whole genome to the anchoring sites of 3D genome architecture.

Results: 7 significant CCSs were found over the HLA-C, HLA-B and TNF regions on Chromosome 6 in the early phenotype. The top 8 pathways for genetic locations associated to the CCSs are shown in Table 1.

Table 1. Top 8 pathways for genetic locations associated to significant CCS for the early phenotype.

	GeneSet
1	Natural Killer cell mediated cytotoxicity
2	Immunoregulatory interactions between a lymphoid cell and a non-lymphoid cell
3	Antigen Processing & presentation
4	Phagosome
5	Graft versus host disease
6	Type 1 diabetes mellitus
7	Osteoclast differentiation
8	Class 1 MHC mediated antigen processing & presentation

2 significant CCSs were found centred around the IFNG region of chromosome 12 in the late phenotype. The top 8 pathways for genetic locations associated to significant CCSs are shown in Table 2.

Table 2. Top 8 pathways for genetic locations associated to significant CCS for the late phenotype.

	GeneSet
1	Surfactant metabolism
2	IL12 signalling mediated by STAT4
3	Protein digestion & absorption
4	Calcineurin regulated NFAT dependent transcription in lymphocytes
5	Transcriptional misregulation in cancer
6	Kaposi's sarcoma associated herpes virus infection
7	IL2 mediated signalling events
8	Inflammatory bowel disease

Conclusion: Significant CCSs, as part of 3D genomic regulatory control, and their associated pathways for the genetic locations, were identified in both late and early phenotypes. There were distinct CCSs in the early phenotype compared to the late suggesting the CCSs change as the disease progresses and varies between phenotypes. If CCSs could be linked to each clinically defined subgroup across a SSc cohort they could be used as a biomarker tool to predict outcome and progression in patients.

Disclosure of Interests: Megan Galloway: None declared, Ewan Hunter: None declared, Alexandre Akoulitchev: None declared, Shivanee Vigneswaran: None declared, Bahja Abdi: None declared, Christopher Denton Grant/research support from: GlaxoSmithKline, Inventiva, CSF Behring, Consultant of: Roche-Genentech, Actelion, GlaxoSmithKline, Sanofi Aventis, Inventiva, CSL Behring, Boehringer Ingelheim, Bayer, David Abraham: None declared, Richard Stratton: None declared

DOI: 10.1136/annrheumdis-2020-eular.6323

PARE abstract session

OP0255-PARE

USING AN EDUCATIONAL APPLICATION TO FACILITATE UNDERSTANDING OF THE ANATOMY AND FUNCTION OF THE BRAIN AND TO EXPLORE THE EFFECTS OF CLINICAL FATIGUE FROM A PATIENT PERSPECTIVE

J. Zurowski¹, C. Wright², N. Basu², M. Poyade¹, L. Bennett². ¹The Glasgow School of Art, School of Simulations and Visualisation, Glasgow, United Kingdom; ²University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

Background: Rheumatic and musculoskeletal diseases are a group of devastating autoimmune disorders that all commonly share the debilitating symptom of fatigue. Despite the fact that fatigue can often cause some of the greatest impairments to quality of life, it is frequently reported by patients as the least successfully managed symptom of these conditions.

Fatigue is routinely misunderstood within the general population, with many people using the word fatigue as a synonym for tired. Fatigue is not the same as tiredness, which is a normal state that is experienced by most of the population, therefore it is important to help the general public understand what fatigue actually is and how it imposes consequences and limitations on those who suffer from it. To aid this understanding an educational application has been created to reinforce the patient perspective of living with fatigue. Furthermore, this application will also aid the understanding of brain anatomy and function, using Augmented Reality (AR), as research has now shown that brain function may be altered in the state of fatigue. Currently, educational AR applications show great potential for increasing comprehension and understanding of complex concepts. AR expands user engagement by enhancing the learner's enjoyment and enriching their learning environment. We hope to utilise this technology in the education of fatigue.